Details for New Drug Application (NDA): 213213
✉ Email this page to a colleague
NDA 213213 describes AMINOCAPROIC ACID, which is a drug marketed by Abraxis Pharm, Baxter Hlthcare, Hospira, Luitpold, Amneal, Annora Pharma, Aurobindo Pharma, Belcher, Carnegie, Epic Pharma Llc, Florida, MSN, Sunny, Taro, Trupharma, Vistapharm Llc, Adaptis, Ani Pharms, and Appco, and is included in twenty-four NDAs. It is available from seventeen suppliers. Additional details are available on the AMINOCAPROIC ACID profile page.
The generic ingredient in AMINOCAPROIC ACID is aminocaproic acid. There are six drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the aminocaproic acid profile page.
The generic ingredient in AMINOCAPROIC ACID is aminocaproic acid. There are six drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the aminocaproic acid profile page.
Summary for 213213
| Tradename: | AMINOCAPROIC ACID |
| Applicant: | Sunny |
| Ingredient: | aminocaproic acid |
| Patents: | 0 |
Pharmacology for NDA: 213213
| Physiological Effect | Decreased Fibrinolysis |
Medical Subject Heading (MeSH) Categories for 213213
Suppliers and Packaging for NDA: 213213
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| AMINOCAPROIC ACID | aminocaproic acid | SOLUTION;ORAL | 213213 | ANDA | Vitruvias Therapeutics | 69680-114 | 69680-114-08 | 236.5 mL in 1 BOTTLE (69680-114-08) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 0.25GM/ML | ||||
| Approval Date: | Dec 27, 2023 | TE: | AA | RLD: | No | ||||
Complete Access Available with Subscription
